Using fecal microbiota transplant and fiber to treat gut graft versus host disease
A Randomized, Controlled, Phase I Study of Fecal Microbiota Transplant and Dietary Fiber Supplementation in Graft Versus Host Disease
This study is testing whether a combination of fecal microbiota transplant and fiber can help people with gut graft versus host disease feel better.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fred Hutchinson Cancer Center Academic / other |
| Drugs / interventions | Immunotherapy |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT05067595 on ClinicalTrials.gov |
What this trial studies
This phase I trial investigates the effectiveness of fecal microbiota transplant (FMT) combined with dietary fiber supplementation in treating patients suffering from gut graft versus host disease (GvHD). Participants are randomized into four groups, receiving either upper or lower FMT through different methods, with some also receiving fiber supplementation. The study aims to modify the gut microbiome to alleviate symptoms of GvHD. Throughout the trial, various biological samples will be collected for analysis, and patients will be monitored for a year after treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have undergone allogeneic hematopoietic stem cell transplant within the past year and are experiencing mild to severe acute gastrointestinal GvHD.
Not a fit: Patients with a history of serious adverse events related to fecal microbiota transplant or recent gastrointestinal complications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the management and outcomes of patients with gut graft versus host disease.
How similar studies have performed: Other studies have shown promise in using fecal microbiota transplant for various gastrointestinal conditions, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * History of allogeneic hematopoietic stem cell transplant in the past 365 days * Post-engraftment, defined by time period following three consecutive days of sustained neutrophil engraftment with an absolute neutrophil count of at least 500 cells/mm\^3 * Mild to severe acute GI GvHD, at least stage 1, as measured by one of the following: * Modified Glucksberg criteria for GI GvHD averaged over 3 consecutive days and without another explanation for diarrhea such as laxative use or infection. In patients who have already had GI biopsy, biopsy histology must be compatible with GVHD, although biopsy is not required * Biopsy evidence of GI GVHD in the upper or lower GI tract Exclusion Criteria: * History of previous serious adverse events associated with FMT * History of bowel perforation in the last 90 days * History of gastrointestinal resection in the last 90 days * History of intestinal obstruction in the last 90 days * History of diverticulitis in the last 90 days * History of celiac disease confirmed by serologic testing or small bowel biopsy * History of severe dietary allergy as designated by World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System grade 2 or more * Subjects who are cytomegalovirus (CMV) seronegative at the time of enrollment as indicated by clinical testing unless the fecal microbiota transplant (FMT) donor is CMV seronegative with negative plasma polymerase chain reaction (PCR) assays for CMV. * Known allergies to loperamide, sodium chloride, glycerol, theobroma oil, hide bovine gelatin, sodium lauryl sulfate, colorants FD\&C, titanium dioxide, polyethylene glycol, sodium sulfate, sodium bicarbonate, sodium phosphate, benzalkonium chloride, disodium EDTA or potassium chloride. * Currently pregnant, planning to become pregnant or breastfeeding during the study period. Women of childbearing potential (those who are not post-menopausal or post-hysterectomy) must be negative for pregnancy per urine pregnancy test at enrollment * Individuals with the ability to conceive children who are not willing to abstain from sexual activity or use an effective form of birth control during the duration of the study * Unwilling or unable to participate in study procedures including oral intake of FMT, colonoscopy, fiber supplementation, collection of stool samples and completion study surveys * Cannot reasonably and safely participate in the study in the opinion of the investigators
Where this trial is running
Seattle, Washington
- Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: David Fredricks — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: David Fredricks
- Email: dfredric@fredhutch.org
- Phone: 206.667.1935
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.